Health Canada first announced in 2019 that the Patented Medicine Prices Review Board would change how it sets a price cap on medicines in Canada in an effort to lower excessively expensive drug costs by changing the countries Canada compares prices with.
The government says the changes offer more flexibility around licensing requirements and harmonize pharmacy requirements with the Health Professions Act.
Alok Kanti, President and Chief Executive Officer of Bayer Canada, will be the new chair for the organization, which represents Canada’s pharmaceutical industry.
The organization is looking for someone with in-depth knowledge of regulatory affairs in the pharmaceutical industry and someone who is an expert in toxicology and drug information.
